Add Bernie Sanders' name to the long list of people who hate that CEO who massively inflated the cost of an AIDS drug.

The Vermont senator has rejected a donation from the former hedge fund manager who raised the price of an AIDS drug from $13.50 to $750 per pill, the campaign confirmed Thursday.

Martin Shkreli, the Turing Pharmaceuticals CEO who received a generous helping of Internet vitriol last month after his company bought the rights to the life-saving drug Daraprim — and then promptly raised its price by more than 5,000% — requested a meeting with Sanders and donated $2,700 to the socialist-leaning democrat's campaign.

But Sanders, an outspoken critic of prescription price gouging, said through a campaign spokesman Thursday that Shkreli's contribution would be donated to Whitman-Walker Health, a Washington, D.C. center specializing in the treatment of HIV/AIDS, on Friday.

Martin Shkreli is pictured in a photo from what appeared to be his Twitter account. Image: Martin Shkreli/Twitter

"He is the poster boy for pharmaceutical company greed," Sanders spokesman Michael Briggs told Mashable. "We don't want his stinkin' money."

Briggs confirmed that Shkreli made the donation through ActBlue, an online political fundraising platform, on Sept. 28.

Shkreli first mentioned the donation in a tweet during the Democratic debate Tuesday. He said he was inspired to make the contribution, the maximum amount an individual can donate to a campaign, by Sanders' platform, but admitted to the Stat that his main motivation was to meet with Sanders in order to explain how his and other pharmaceutical companies set drug prices.

Damn @BernieSanders is my boy with that Kosovo reference. Gets my full endorsement. I did donate to him... — Martin Shkreli (@MartinShkreli) October 14, 2015

Shkreli sparked outrage last month after the New York Times reported that his company had obtained the rights to sell the 62-year-old drug Daraprim and hiked up its price virtually overnight. The drug is used to fight a rare parasitic infection in those with weakened immune systems, including AIDS patients and infants.

In response to the backlash, Shkreli told the New York Times that the price hike was intended to fund the research and development of new drugs, however critics have been skeptical of his claims. Shkreli also promised to eventually lower Daraprim's price, but told Business Insider that it would take a "long time" to determine a more reasonable market value.

In response to Shkreli's failure to make Daraprim more affordable, Sanders and Rep. Elijah Cummings, a Democrat from Maryland, denounced prescription price gouging last week in a statement specifically aimed at Turing Pharmaceuticals and its CEO.

“On behalf of the American people, we are sickened by these actions," the statement read. "Mr. Shkreli is holding hostage the patients who rely on this lifesaving medication, as well as the hospitals that administer it, by charging unconscionable prices for a drug on which he has a monopoly—just because he can."

The greed of the pharmaceutical industry is a public health hazard to the American people. — Bernie Sanders (@SenSanders) October 9, 2015

Meanwhile, Shkreli has responded to Sanders' rejection with about as much maturity as he's addressed all of his critics so far.